Related Experiment Video
Updated: Jul 4, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Onset and progression of the Anderson-Fabry disease related cardiomyopathy
Christoph Kampmann1, Ales Linhart, Frank Baehner
1University Children's Hospital Mainz, Germany.
Insights
Cardiac involvement in Anderson-Fabry disease (AFD) leads to significant health issues. This study found left ventricular hypertrophy (LVH) is common in both males and females with AFD, but onset is later and progression slower in females.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Cardiac involvement is a major cause of morbidity and mortality in Anderson-Fabry disease (AFD).
- Understanding the onset and progression of cardiac issues in AFD is crucial for patient management.
- This study focuses on documenting cardiac changes in a cohort of AFD patients.
Purpose of the Study:
- To document the onset and progression of cardiac involvement in male and female Anderson-Fabry disease patients.
- To analyze the correlation between age and left ventricular mass indexed (LVMi) in AFD.
- To compare the prevalence and progression rates of left ventricular hypertrophy (LVH) between genders.
Main Methods:
- Cross-sectional echocardiographic study of 177 male and female AFD patients.
- Longitudinal follow-up of 76 patients (38 males, 38 females) over a mean of 4.5 years without enzyme replacement therapy.
- Analysis of left ventricular mass indexed (LVMi) and prevalence of left ventricular hypertrophy (LVH).
Main Results:
- A significant correlation between age and LVMi was observed in both males and females with AFD (P<0.0001).
- Initial LVH prevalence was 48.6% in males and 36.4% in females, peaking at ages 40 and 60, respectively.
- LVMi increased annually by 4.07 g/m(2.7) in males and 2.31 g/m(2.7) in females (P<0.01).
Conclusions:
- Anderson-Fabry disease is associated with a high prevalence of left ventricular hypertrophy in both genders.
- The onset of LVH in AFD is delayed in females compared to males.
- The rate of LVH progression is slower in females with AFD.
Background:
Cardiac involvement is responsible for substantial morbidity and mortality in Anderson-Fabry disease (AFD). We sought to document its onset and progression in a population of male and female AFD patients.
Methods:
We performed a cross sectional echocardiographic study of a cohort of 177 male and female AFD patients with subsequent longitudinal follow-up of 76 patients (38 males and 38 females; mean follow-up 4.5 years) who did not receive enzyme replacement therapy.
Results:
In this population, aged 3.3 to 70.8 years, a strong correlation between age and left ventricular mass indexed (LVMi, g/m(2.7)) was found in both males and females (P<0.0001 for both). At the initial examination 48.6% of the male patients and 36.4% of the female patients were classified as having left ventricular hypertrophy (LVH). The cumulative prevalence of LVH peaked at age 40 years in males and 60 years in females. In patients with longitudinal follow-up, LVMi increased by 4.07+/-1.03 g/m(2.7) per year in males and by 2.31+/-0.81 g/m(2.7) in females (P<0.01, Wilcoxon rank sum). In patients with LVH at baseline, the median progression rate was 5.52 g/m(2.7) per year in males and by 1.80 g/m(2.7) in females (P=0.12).
Conclusion:
AFD is associated with high prevalence of LVH in both genders. However, the age of onset is delayed in females and progression rate slower.
More Related Videos
08:38A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
Published on: July 21, 2023
09:40Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
Published on: January 19, 2017
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Rheumatic Heart Disease I: Introduction
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis I: Introduction